Brain metastases are a common and severe complication of metastatic breast cancer (MBC), with approximately 20% to 30% of patients experiencing brain metastases[1]. Among these, the incidence of brain metastases in HER2-positive MBC patients can reach 30% to 55%[2]; the incidence is also high in HER2-negative patients[3]. This makes MBC the second leading cause of … Read more
Brain metastases are a common and severe complication of metastatic breast cancer (MBC), with approximately 20% to 30% of patients experiencing brain metastases[1]. Among these, the incidence of brain metastases in HER2-positive MBC patients can reach 30% to 55%[2]; the incidence is also high in HER2-negative patients[3]. This makes MBC the second leading cause of … Read more
Since the emergence of several new drugs for the treatment of solid tumors, such as larotrectinib and entrectinib, the concept of “broad-spectrum anti-cancer drugs” has officially entered public awareness. Years later, more and more broad-spectrum anti-cancer drugs have moved from the laboratory to clinical settings, officially ushering in this precise yet “broad-spectrum” era of cancer … Read more